Agilent Technologies Inc (A) fair value: what the stock is really worth
As of Nov 4, 2026: fair value (intrinsic value) of Agilent Technologies Inc stock $64.53, price $177, that is 63.6% below the price, quality 71 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range $98.15 – $181.48 · fair‑value band $43.36 – $89.58 · the $177.17 price screens above the $64.53 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 4, 2026.
Follow Agilent Technologies in your weekly email
Every Wednesday you see whether Agilent Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Show moreShow less
The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems.
This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses.
The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services.
This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise.
In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software.
The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce.
Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Stock analysis
Agilent Technologies Inc (A) currently trades at $177.17, while our model-based Fair Value estimate is $64.53, 64% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $79.00 per share, and 0 of the 24 models we run sit above the $177.17 price.
Bear case: the Dividend Discount group reads lowest at $11.91, and 24 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: $43.36 (bear) to $89.58 (bull), the price of $177.17 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Agilent Technologies Inc reported revenue of $6.9B in FY2025 versus $6.3B in FY2021, a compound +2.4%/yr. Reported net income was $1.3B in FY2025, compounding +1.9%/yr from FY2021.
Key figures
Market cap $50.1B Large · P/E ratio 34.9 · P/S ratio 6.80 · EPS (TTM) $5.07 · Dividend yield 0.6% · Net margin 19.5% · Return on equity 21.0% · Return on assets (EBIT) 12.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 80 out of 100 (medium confidence).
What moves the price
The share trades about 2% below its 52-week high and 62% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −64%, A screens richer than that median.
Fair Value models
Bear$43.36Fair Value $64.53Bull$89.58
Price $177.17 · Downside -63.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($4.06 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director sold shares worth $312,647 and none bought.
SaleMikael DolstenDirector3× since Dec 1, 2025: 4,834 shares, avg. $145.25$702,153Sep 4, 2026
SaleRodney GonsalvesV.P., Corporate Controller3,000 shares at $154.99$464,970Nov 26, 2025
SalePadraig McDonnellPresident and CEO, Director2× since Nov 12, 2025: 13,401 shares, avg. $149.54$2.0MNov 18, 202510b5-1 plan
Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.80/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Start year 2020 (pandemic). Over 10 years: +5.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+7.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.4%
Dividend (yield on the price)0.6%
Per share before 2014divided by the spin-off factor 1.398
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6.4% vs 12.6%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 21%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+24.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +21.9% a year for the price and +3.9% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Agilent's business benefits from a moderate moat driven by pricing power and solid margins in diagnostics, yet it is held back by limited ownership signals and average human capital indicators.
Main risk: Generative AI and lab automation could reduce demand for Agilent's analytical instruments via higher throughput and AI pre-screening in drug discovery while commoditising its recurring data analysis software revenue.
Bull case: Agilent could integrate AI into its instruments and workflows to boost productivity and expand demand for its hardware and services in automated labs.
Bear case: If AI-driven automation and pre-screening take hold, Agilent's instrument sales and software margins could decline as labs need fewer devices and turn to open-source alternatives.
Agilent is adding lab space in Boulder to scale enzymatic ligation for oligonucleotide therapeutics such as siRNA and ASOs through its Advanced Therapeutics division. Initial customer programs are slated to start next month, complementing existing operations in Colorado and Canada. Our models currently see the stock as overvalued. Will this manufacturing expansion deliver meaningful new revenue streams or mainly increase costs while core diagnostics demand stays subdued?
Compare Agilent Technologies Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 7/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside−63.6% · Bottom 25%
Profitability
Return on equity (12 months)21.0% · Top 25%
Return on assets10.2% · Top 25%
Net margin (12 months)19.5% · Top 25%
Operating margin (12 months)25.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)8.1% · Above median
Dividend yield (12 months)0.6% · Below median
Balance sheet
Debt / equity0.45× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)34.9× · Pricier than median
P/B7.44× · Priciest 25%
P/S (12 months)6.80× · Priciest 25%
Price / free cash flow43.5× · Pricier than median
EV/EBITDA24.7× · Pricier than median
PEG1.37× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)41· sector 38
PAST (return on equity)84· sector 15
HEALTH (low debt)77· sector 95
DIVIDEND (yield)11· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Agilent Technologies Inc (A) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $64.53 versus a price of $177.17, about 64% lower (overvalued).
What is the fair value of A?
Our model-based fair value for Agilent Technologies Inc is $64.53 (as of Nov 4, 2026), built from audited fundamentals. The current price: $177.17.
What is the quality score of A?
Agilent Technologies Inc has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Agilent Technologies Inc (A)?
Our model-based price target is the fair value of $64.53 (as of Nov 4, 2026) from 24 valuation models. Cautious scenario $43.36, optimistic scenario $89.58. It is a calculation from audited fundamentals, not an analyst target.
What is the Agilent Technologies Inc stock forecast for 2026?
Our models put fair value at $64.53, about 64% lower versus a price of $177.17 (overvalued). Cautious scenario $43.36, optimistic scenario $89.58. The calculation is refreshed regularly with new filings.
What is the revenue of Agilent Technologies Inc (A)?
Agilent Technologies Inc reported trailing-twelve-month revenue of about $7.4B (latest available figure, as of Nov 4, 2026).
Does Agilent Technologies Inc pay a dividend?
Agilent Technologies Inc currently shows a dividend yield of 0.57% relative to its recent price (as of Nov 4, 2026).
What growth is priced into Agilent Technologies Inc (A)?
For today's price to be fair in a discounted-cash-flow model, Agilent Technologies Inc would have to grow free cash flow by +24.8 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.4 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of A use?
Our models discount Agilent Technologies Inc at 9.7 %: a base by market capitalisation (large), damped by beta 1.21, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Agilent Technologies Inc that is +24.8 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Agilent Technologies Inc (A) delivered so far?
Over the past 5 years revenue at Agilent Technologies Inc grew +5.4 % a year. The price currently implies +24.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Agilent Technologies Inc (A) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Agilent Technologies Inc (+24.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Agilent Technologies Inc (A)?
The free-cash-flow yield on the price is 2.30 %: that much free cash flow Agilent Technologies Inc produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Agilent Technologies Inc (A)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Agilent Technologies Inc it is $64.53 per share (as of Nov 4, 2026), against a price of $177.17. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Agilent Technologies Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, A trades above its calculated fair value: price $177.17, fair value $64.53, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of A?
No. The price is what the market pays today ($177.17); the fair value is what the company's own numbers justify ($64.53). For Agilent Technologies Inc the two are $112.64 per share apart. That gap is exactly why we show both numbers side by side.
How much is Agilent Technologies Inc worth?
The market values Agilent Technologies Inc at about $50.1B (market capitalisation, as of Nov 4, 2026). Per share that is $177.17; our models calculate a fair value of $64.53 per share.
What do the bullish and bearish scenarios say about A?
Our models span a range for Agilent Technologies Inc: cautious scenario $43.36, base $64.53, optimistic $89.58 per share (as of Nov 4, 2026, price $177.17). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of A?
Agilent Technologies Inc trades at a price-to-earnings ratio of 34.9 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $64.53 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 32.2. Other multiples: PEG 1.4, P/B 7.4, P/S 6.8, EV/EBITDA 24.7.
What is the PEG ratio of A?
The PEG ratio of Agilent Technologies Inc is 1.37 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Agilent Technologies Inc (A)?
Balance-sheet figures for Agilent Technologies Inc (as of Nov 4, 2026): return on equity 21.0%, debt of 0.45 per unit of equity. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is A from its 52-week high?
Agilent Technologies Inc trades at $177.17, about 2% below its 52-week high of $181.48 and 62% above the low of $109.61 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of $64.53 is for.
Which stocks are comparable to Agilent Technologies Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Agilent Technologies Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $177.17, calculated fair value $64.53 (−64%), Quality Score 71/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of A calculated?
We run Agilent Technologies Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $64.53, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Agilent Technologies Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Agilent Technologies Inc (A)?
The closing price on Nov 4, 2026 was $177.17. Our model-based fair value is $64.53, about 64% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Agilent Technologies Inc right now?
The price sits above even our optimistic bull case ($89.58). The favourable scenario is already priced in. Solid but not exceptional quality (71/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($43.36 to $89.58) leaves room in how you read the outcome.
Where does the earnings growth of Agilent Technologies Inc (A) come from?
Earnings per share at Agilent Technologies Inc grew +13.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.4 %, EBIT margin +5.9 %, tax rate −0.4 %, residual (interest, one-offs) +0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Agilent Technologies Inc
How large is the market capitalisation of Agilent Technologies Inc (A)?
The market capitalisation of Agilent Technologies Inc is $50.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Agilent Technologies Inc (A)?
The price-to-sales ratio of Agilent Technologies Inc is 6.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Agilent Technologies Inc (A)?
Earnings per share at Agilent Technologies Inc are $5.07 (price ÷ EPS = P/E 34.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Agilent Technologies Inc (A)?
The dividend yield of Agilent Technologies Inc is 0.6% (payout 20.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Agilent Technologies Inc (A)?
The net margin of Agilent Technologies Inc is 19.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Agilent Technologies Inc (A)?
The return on equity (ROE) of Agilent Technologies Inc is 21.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Agilent Technologies Inc (A)?
On an EBIT basis the return on assets of Agilent Technologies Inc is 12.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Agilent Technologies Inc (A)?
The operating margin of Agilent Technologies Inc is 25.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Agilent Technologies Inc (A)?
Revenue at Agilent Technologies Inc is growing +8.1% versus a year earlier (3y avg +0.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Agilent Technologies Inc (A)?
Earnings per share at Agilent Technologies Inc are growing +8.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Agilent Technologies Inc (A) carry?
The net debt of Agilent Technologies Inc is $1.6B (fiscal year 2025, ≈ 1.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Agilent Technologies Inc in the live analysis
One click puts Agilent Technologies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 4, 2026